Key Points
- CEO Matthew Klein sold 8,089 PTC Therapeutics shares on Dec. 30 at an average price of $76.64, totaling about $619,941, reducing his stake by 2.31% to 341,875 shares (SEC Form 4 filed).
- PTCT trades around $76.7 with a $6.16B market cap and a PE of 8.96; the company recently beat quarterly expectations (EPS $0.20 vs. -$1.19 est., revenue $211M vs. $177M) while analysts hold a consensus "Hold" rating and $76 target.
PTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) CEO Matthew Klein sold 8,089 shares of the stock in a transaction on Tuesday, December 30th. The shares were sold at an average price of $76.64, for a total transaction of $619,940.96. Following the transaction, the chief executive officer owned 341,875 shares of the company's stock, valued at $26,201,300. This trade represents a 2.31% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
PTC Therapeutics Stock Up 1.0%
PTC Therapeutics stock opened at $76.74 on Friday. The company's 50-day moving average price is $75.68 and its 200-day moving average price is $61.79. The company has a market cap of $6.16 billion, a PE ratio of 8.96, a price-to-earnings-growth ratio of 0.27 and a beta of 0.49. PTC Therapeutics, Inc. has a twelve month low of $35.95 and a twelve month high of $87.50.
PTC Therapeutics (NASDAQ:PTCT - Get Free Report) last released its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.20 EPS for the quarter, topping the consensus estimate of ($1.19) by $1.39. PTC Therapeutics had a negative return on equity of 194.11% and a net margin of 42.25%.The company had revenue of $211.01 million during the quarter, compared to analyst estimates of $177.42 million. During the same quarter last year, the business posted ($1.39) earnings per share. The firm's revenue was up 7.2% on a year-over-year basis. As a group, sell-side analysts expect that PTC Therapeutics, Inc. will post -4.52 earnings per share for the current fiscal year.
Institutional Trading of PTC Therapeutics
Large investors have recently modified their holdings of the company. Smartleaf Asset Management LLC increased its holdings in PTC Therapeutics by 101.3% during the 3rd quarter. Smartleaf Asset Management LLC now owns 469 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 236 shares during the period. Optiver Holding B.V. grew its position in shares of PTC Therapeutics by 96.5% during the 3rd quarter. Optiver Holding B.V. now owns 507 shares of the biopharmaceutical company's stock worth $31,000 after buying an additional 249 shares in the last quarter. Comerica Bank increased its stake in shares of PTC Therapeutics by 868.5% during the third quarter. Comerica Bank now owns 523 shares of the biopharmaceutical company's stock valued at $32,000 after buying an additional 469 shares during the period. IFP Advisors Inc raised its holdings in shares of PTC Therapeutics by 68.1% in the third quarter. IFP Advisors Inc now owns 765 shares of the biopharmaceutical company's stock valued at $47,000 after acquiring an additional 310 shares in the last quarter. Finally, PNC Financial Services Group Inc. raised its holdings in shares of PTC Therapeutics by 42.1% in the second quarter. PNC Financial Services Group Inc. now owns 995 shares of the biopharmaceutical company's stock valued at $49,000 after acquiring an additional 295 shares in the last quarter.
Analyst Ratings Changes
Several analysts recently weighed in on the company. Barclays increased their price target on PTC Therapeutics from $46.00 to $68.00 and gave the company an "equal weight" rating in a report on Wednesday, November 5th. Jefferies Financial Group increased their target price on shares of PTC Therapeutics from $63.00 to $77.00 and gave the company a "buy" rating in a research note on Tuesday, October 28th. Cowen restated a "hold" rating on shares of PTC Therapeutics in a report on Wednesday, November 5th. Wall Street Zen upgraded shares of PTC Therapeutics from a "hold" rating to a "buy" rating in a report on Saturday. Finally, Citigroup increased their price objective on shares of PTC Therapeutics from $50.00 to $75.00 and gave the stock a "neutral" rating in a research report on Wednesday, November 5th. Nine analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $76.00.
Read Our Latest Report on PTCT
PTC Therapeutics Company Profile
(
Get Free Report)
PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company's research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.
Among PTC's approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
